within Pharmacolibrary.Drugs.ATC.C;

model C02DB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.2,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02DB03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Endralazine is a hydrazinophthalazine derivative antihypertensive drug that acts as a vasodilator, formerly used in the management of hypertension. It is not widely used today and does not appear to be marketed or approved in most countries currently.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a typical adult following oral administration, as no published clinical pharmacokinetic studies have been found for endralazine.</p><h4>References</h4><ol><li><p>Meredith, PA, et al., &amp; Reid, JL (1983). The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. <i>British journal of clinical pharmacology</i> 16(1) 27–32. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1983.tb02139.x&quot;>10.1111/j.1365-2125.1983.tb02139.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6882620/&quot;>https://pubmed.ncbi.nlm.nih.gov/6882620</a></p></li><li><p>Elliott, HL, et al., &amp; Reid, JL (1984). Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives. <i>International journal of clinical pharmacology research</i> 4(1) 61–69. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6469433/&quot;>https://pubmed.ncbi.nlm.nih.gov/6469433</a></p></li><li><p>Kindler, J, et al., &amp; Pacha, W (1987). Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine. <i>European journal of clinical pharmacology</i> 32(4) 367–372. DOI:<a href=&quot;https://doi.org/10.1007/BF00543971&quot;>10.1007/BF00543971</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3609114/&quot;>https://pubmed.ncbi.nlm.nih.gov/3609114</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02DB03;
